Rag1-KO(Rag1-EGFP)

A loxP-EGFP-PolyA-loxP-Neo-loxP expression cassette was knocked into the Rag1 gene start codon site. As a Rag1 knockout mouse model, this stain can be used in subcutaneous inoculation of liver cancer tissues and tumor cells. Tumors can esaily form and grow. The amount of T and B lymphocytes in peripheral blood of mice was extremely low tested by FACS, which was comparable to or lower than that of Nude mice, and there was a significant difference compared with wild type mice. The pathological sections of HE staining of tumor tissues showed that the tumor sections of Rag1 KO mice and Nude mice were similar. This strain has the potential to replace Nude, NOD-SCID mice as a tumor-bearing mouse model.

Fig.1 Construction strategy of Rag1-KO.

Fig.2 Loss of T and B cells in peripheral blood of Rag1-KO and Rag2-KO mice.

Fig.3 Loss of T and B cells in Spleen of Rag1-KO and Rag2-KO mice.

Fig.4 Loss of T and B cells in thymus of Rag1-KO and Rag2-KO mice.

Fig.5 Detection of mouse IgG(A) and IgM(B) expression in serum by ELISA. (male, 5~6wks, n=3)

Abbr. HO, homozygous; WT, wild type; N.D. not detected.

Fig.6 Tumorigenicity results following inoculation with A549 tumor cells in Balb/c nude, NOD-Scid, Rag1-KO and Rag2-KO mice.

Table1. Complete blood count of Rag1-KO (Rag1-EGFP) mice

Table 2. Serum biochemical analysis of Rag1-KO (Rag1-EGFP) mice.

Programmed death protein 1 is essential for maintaining the anti-inflammatory function of infiltrating regulatory T cells in a murine spinal cord injury model
References：Journal of Neuroimmunology

Peli1 negatively regulates noncanonical NF-κB signaling to restrain systemic lupus erythematosus
References：Nature Communications

Interleukin-17 Regulates Neuron-Glial Communications, Synaptic Transmission, and Neuropathic Pain after Chemotherapy
References：Cell Reports

Tpl2 Protects Against Fulminant Hepatitis Through Mobilization of Myeloid-Derived Suppressor Cells
References：Frontiers in Immunology

Gut Microbial Metabolite Pravastatin Attenuates Intestinal Ischemia/Reperfusion Injury Through Promoting IL-13 Release From Type II Innate Lymphoid Cells via IL-33/ST2 Signaling
References：Frontiers in Immunology